Original Article
Modern Pathology (2004) 17, 109–116. advance online publication, 5 December 2003; doi:10.1038/modpathol.3800039
Caspase-3 activation in systemic anaplastic large-cell lymphoma
This study was presented in part at the XIth Meeting of the European Association for Hematopathology, May 26–30, 2002, Siena, Italy.
Elias Drakos1, George Z Rassidakis1, Raymond Lai1, Marco Herling1,2, Sean L O'Connor3, Annette Schmitt-Graeff2, Timothy J McDonnell3 and L Jeffrey Medeiros1
- 1Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- 2The Institute of Pathology, Albert-Ludwigs-University of Freiburg, Germany
- 3Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Correspondence: LJ Medeiros, Department of Hematopathology, Box 72, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. E-mail: jmedeiro@mail.mdanderson.org
Received 25 June 2003; Accepted 14 October 2003; Published online 5 December 2003.
Abstract
Anaplastic large-cell lymphoma (ALCL), as currently defined, includes a subset of tumors that have abnormalities of chromosome 2p23 (alk gene) resulting in overexpression of anaplastic lymphoma kinase (ALK). We have previously shown differences in apoptotic rate and expression of apoptosis-related proteins between ALK-positive and ALK-negative ALCL. In this study, we assessed for activated caspase-3 (aC-3), an executioner of apoptotic cell death, in ALCL cell lines and tumors. We used the Karpas 299 and SU-DHL-1 cell lines, and the caspase inhibitors Boc-D-FMK and DEVD-FMK to investigate the role of caspase-3 activation in tumor cell death after treatment with doxorubicin. Cell viability and apoptosis were assessed by trypan blue and Annexin-V methods. A caspase-3 assay was used to evaluate caspase-3 enzymatic activity. Caspase-3 activity was significantly increased in Karpas-299 and SU-DHL-1 cells treated with doxorubicin, but remained as low as control levels with addition of Boc-D-FMK or DEVD-FMK. Expression of aC-3 was also assessed immunohistochemically in 57 ALCL tumors. The mean percentage of aC-3 positive tumor cells was 3.2% in ALK-positive ALCL compared with 1.2% in ALK-negative ALCL (P=0.0003, Mann–Whitney test), and inversely correlated with BCL-2 expression (P=0.01, Mann–Whitney test). aC-3 expression did not correlate with patient outcome in either the ALK-positive or ALK-negative ALCL groups. In conclusion, doxorubicin-induced cell death of ALK-positive ALCL cells involves caspase-3 activation in vitro. aC-3 levels correlate with ALK expression in ALCL tumors.
Keywords:
activated caspase-3, anaplastic large-cell lymphoma, ALK, BCL-2, prognosis
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
The anaplastic lymphoma kinase in the pathogenesis of cancer
Nature Reviews Cancer Review (01 Jan 2008)
NEWS AND VIEWS
An enriched look at tyrosine phosphorylation
Nature Biotechnology News and Views (01 Jan 2005)
RESEARCH
Leukemia Original Article
Bone Marrow Transplantation Original Article
Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis
Modern Pathology Original Article

